Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

In a report released today, Thorsten Reigber from DZ BANK AG maintained a Buy rating on Heidelberg Materials (0MG2 – Research Report). The ...

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...